Equities analysts predict that Adial Pharmaceuticals Inc (NASDAQ:ADIL) will post ($0.40) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Adial Pharmaceuticals’ earnings. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 20th.

On average, analysts expect that Adial Pharmaceuticals will report full-year earnings of ($1.32) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($0.31) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Adial Pharmaceuticals.

ADIL has been the subject of several recent analyst reports. Maxim Group restated a “buy” rating and set a $5.00 target price on shares of Adial Pharmaceuticals in a research note on Thursday, December 13th. ValuEngine downgraded Adial Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 21st.

NASDAQ:ADIL opened at $3.31 on Friday. Adial Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $9.44.

Several institutional investors have recently made changes to their positions in ADIL. Two Sigma Investments LP acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter valued at about $60,000. Geode Capital Management LLC acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter valued at about $69,000. Finally, BlackRock Inc. acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter valued at about $1,053,000. Institutional investors own 3.80% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis.

Featured Story: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Adial Pharmaceuticals (ADIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.